Applovin Corporation vs Novavax Inc — how do they compare? Applovin Corporation trades at $306.64 (market cap $106.65B), while Novavax Inc trades at $7.95 (market cap $1.31B). The key difference: Applovin Corporation is far larger — about 81.4× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Applovin Corporation nearer its low. Which is the better fit depends on your goals.
| APP | NVAX | |
|---|---|---|
Market Cap | $106.65B | $1.31B |
Sector | Technology | Health |
52-Week High | $733.60 | $11.19 |
52-Week Low | $318.68 | $6.22 |
Enterprise Value | $107.11B | $889.30M |
Signals from Pluang's Aura AI — not financial advice
AppLovin (APP) trades at $310.95, down 8.27% over 24 hours, reflecting recent bearish momentum after a Q2 2026 earnings miss. The stock shows strong profitability with a 64.58% net income margin and robust revenue growth of 53% YoY in Q2, but faces technical pressure with a bearish signal from moving averages. Recent news highlights a Bank of America downgrade to Neutral on August 11, 2026, citing uncertainty around sustaining 30% revenue growth, contributing to the stock's decline.
The outlook is mixed: strong fundamentals and an 80.77% analyst buy rating with a $556.53 consensus price target suggest upside, but execution risks and technical weakness pose near-term challenges. Investors should weigh high valuation multiples against growth sustainability concerns.
Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.
The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.
Trailing returns across standard periods
Latest headlines on both assets
AppLovin provides a software platform for mobile app developers to market, monetize, and analyze their apps. Its AI-powered tools help developers grow their business by connecting them with global advertising networks.
Read more on APP →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →